Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...

Bladder cancer is the abnormal and rapid growth of mutated bladder cells. It starts along the lining of the bladder and progresses through the organ dysreg | Urinary And Excretory System ...

OSLO, Norway, Feb. 17, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder ...

OSLO, Norway, April 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light ...

Findings from an interim analysis of data show that the addition of blue light cystoscopy to conventional white light significantly improved clinical outcomes in a group of patients with ...

Add Yahoo as a preferred source to see more of our stories on Google. Research shows a urine test looking for genetic markers of bladder cancer can more than halve the number of cystoscopies needed to ...

Researchers developed a urine test that detects bladder cancer, predicts which patients will benefit from immunotherapy ...

A simple urine test developed by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose ...

When using a diagnostic tool, it is common see to more false-positives as the number of true-positives increases ( Table 1). The accuracy of fluorescence cystoscopy is also affected by previous ...

Bladder cancer is one of the most common cancer types in the U.S., according to the National Cancer Institute. It's also one of the most likely types of cancer to recur. Experts are developing ways to ...

Data from patients treated in the late 1990s is now emerging, making it possible to assess the effect of improved detection and subsequent changes in patient management on recurrence rates ( Table 2).